Berenberg analyst Kerry Holford raised the firm’s price target on Novartis (NVS) to CHF 110 from CHF 92 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Controversial Prasad leaving FDA, NYT reports
- Novartis shareholders approve all resolutions proposed by Board of Directors
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Trump Trade: U.S. stocks tumble, oil prices surge after strikes on Iran
- Trump says ‘tariffs have influenced’ Novartis to build 7+ facilities